• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.

作者信息

Narod Steven A, Sopik Victoria, Giannakeas Vasily

机构信息

Women's College Research Institute, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Women's College Research Institute, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

出版信息

Gynecol Oncol. 2016 May;141(2):191-194. doi: 10.1016/j.ygyno.2016.02.020. Epub 2016 Feb 26.

DOI:10.1016/j.ygyno.2016.02.020
PMID:26915499
Abstract
摘要

相似文献

1
Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.我们应该进行卵巢癌筛查吗？对英国卵巢癌筛查协作试验（UKCTOCS）随机试验的评论。
Gynecol Oncol. 2016 May;141(2):191-194. doi: 10.1016/j.ygyno.2016.02.020. Epub 2016 Feb 26.
2
Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?卵巢癌风险算法（ROCA）筛查卵巢癌：是好是坏，还是只是昂贵？
Gynecol Oncol. 2018 Apr;149(1):117-120. doi: 10.1016/j.ygyno.2018.01.029. Epub 2018 Feb 15.
3
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).卵巢癌症状、诊断途径和生存情况-英国卵巢癌筛查协作试验（UKCTOCS）“不筛查”组的人群队列研究。
Gynecol Oncol. 2020 Aug;158(2):316-322. doi: 10.1016/j.ygyno.2020.05.002. Epub 2020 Jun 17.
4
UKCTOCS and the evaluation of screening for ovarian cancer.英国卵巢癌筛查协作试验（UKCTOCS）与卵巢癌筛查评估
Lancet. 2016 Mar 5;387(10022):918. doi: 10.1016/S0140-6736(16)00631-0. Epub 2016 Mar 4.
5
Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.卵巢癌筛查的有效性：来自英国卵巢癌筛查协作试验的一项认识
Womens Health (Lond). 2016 Sep;12(5):475-479. doi: 10.1177/1745505716666096. Epub 2016 Sep 5.
6
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).临床前期浸润性上皮性卵巢癌的卵巢癌症状 - 嵌套在英国卵巢癌筛查协作试验（UKCTOCS）中的探索性分析。
Gynecol Oncol. 2023 Dec;179:123-130. doi: 10.1016/j.ygyno.2023.11.005. Epub 2023 Nov 18.
7
Ovarian cancer screening: UKCTOCS trial.卵巢癌筛查：英国癌症研究中心卵巢癌筛查试验
Lancet. 2016 Jun 25;387(10038):2601-2602. doi: 10.1016/S0140-6736(16)30846-7.
8
Ovarian cancer screening: UKCTOCS trial.卵巢癌筛查：英国癌症预防研究（UKCTOCS）试验
Lancet. 2016 Jun 25;387(10038):2602-2603. doi: 10.1016/S0140-6736(16)30848-0.
9
Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.在经历一次重复筛查后，与退出英国卵巢癌筛查协作试验相关的社会心理因素。
Int J Gynecol Cancer. 2015 Oct;25(8):1519-25. doi: 10.1097/IGC.0000000000000507.
10
Ovarian cancer screening: UKCTOCS trial - Authors' reply.卵巢癌筛查：英国癌症研究（UKCTOCS）试验——作者回复
Lancet. 2016 Jun 25;387(10038):2603-2604. doi: 10.1016/S0140-6736(16)30849-2.

引用本文的文献

1
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.转化研究结果支持在复发性卵巢癌患者中开展ubamatamab（MUC16×CD3双特异性抗体）首次人体研究的方案选择。
Clin Transl Sci. 2024 Dec;17(12):e70082. doi: 10.1111/cts.70082.
2
Novel gene signatures for prognosis prediction in ovarian cancer.新型基因标志物用于预测卵巢癌的预后。
J Cell Mol Med. 2020 Sep;24(17):9972-9984. doi: 10.1111/jcmm.15601. Epub 2020 Jul 14.
3
Parenclitic networks for predicting ovarian cancer.
用于预测卵巢癌的旁系亲属网络。
Oncotarget. 2018 Apr 27;9(32):22717-22726. doi: 10.18632/oncotarget.25216.
4
Ovarian cancer statistics, 2018.卵巢癌统计数据，2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
5
Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.卵巢癌标本中错配修复（MMR）基因种系突变与微卫星不稳定性之间的相关性。
Fam Cancer. 2017 Jul;16(3):351-355. doi: 10.1007/s10689-017-9973-1.
6
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.绝经后女性卵巢癌筛查的成本效益：基于模型的经济学评估
BMC Med. 2016 Dec 6;14(1):200. doi: 10.1186/s12916-016-0743-y.
7
Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.卵巢癌筛查的有效性：来自英国卵巢癌筛查协作试验的一项认识
Womens Health (Lond). 2016 Sep;12(5):475-479. doi: 10.1177/1745505716666096. Epub 2016 Sep 5.
8
Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.使用无创产前检测平台检测早期卵巢癌患者血浆DNA异常图谱：对癌症筛查的意义
BMC Med. 2016 Aug 24;14(1):126. doi: 10.1186/s12916-016-0667-6.
9
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.用于检测卵巢癌的新型生物标志物组合的验证
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.